MNPR
VENTE TOTALE: 14 464 titres (~1 581 720,76 $ US)
- Insiders
- Tsuchimoto Kim R, Anderson Raymond
- Total bought
- —
- Total sold
- $1,581,721
- Last activity
- 2026-08-26
- Last synced
-
2026-09-01 10:09:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-01
MNPR is a pre-revenue, cash-burning speculative biotech with no operational income and no clear path to profitability, making its strong liquidity score (85) a temporary buffer rather than a sign of financial health.
The first sentence of the analysis written for MNPR on 2026-09-01 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 51.353 | 11.475 | 4.172 | 4.208 | 12.984 | |
| Quick Ratio | 51.353 | 11.475 | 4.172 | 4.208 | 12.984 | |
| Solvency Ratio | -4.746 | -2.966 | -4.781 | -3.352 | -5.760 | |
| Cash Ratio | 22.606 | 8.720 | 4.135 | 2.616 | 12.846 | |
| Price To Earnings Ratio | -35.297 | -16.176 | -2.931 | -14.277 | -21.986 | |
| Price To Earnings Growth Ratio | -0.980 | -0.120 | 0.097 | -1.042 | -0.850 | |
| Forward Price To Earnings Growth Ratio | -0.980 | -0.120 | 0.097 | -1.042 | -0.850 | |
| Price To Earnings Diluted Ratio | -35.297 | -16.176 | -2.931 | -14.277 | -21.986 | |
| Price To Earnings Diluted Growth Ratio | -0.980 | -0.120 | 0.097 | -1.042 | -0.850 | |
| Price To Book Ratio | 3.511 | 4.574 | 4.415 | 14.937 | 10.568 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -39.663 | -39.312 | -3.139 | -20.849 | -27.356 | |
| Price To Operating Cash Flow Ratio | -39.663 | -39.312 | -3.139 | -20.849 | -27.356 | |
| Debt To Assets Ratio | 0.001 | 0.000 | 0.000 | 0.001 | 0.000 | |
| Debt To Equity Ratio | 0.001 | 0.000 | 0.000 | 0.001 | 0.000 | |
| Debt To Capital Ratio | 0.001 | 0.000 | 0.000 | 0.001 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.021 | 1.095 | 1.315 | 1.311 | 1.083 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.461 | -1.219 | -4.472 | -2.310 | -4.630 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -78.759 | 0.000 | 0.000 | -859.724 | 0.000 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -7,317,401.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -7,317,401.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -30.784 | -13.213 | -2.071 | -13.554 | -19.759 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 51.353 | ▲39.879 | ▲34.515 |
| Quick Ratio | 51.353 | ▲39.879 | ▲34.515 |
| Solvency Ratio | -4.746 | ▼-1.780 | ▼-0.425 |
| Cash Ratio | 22.606 | ▲13.886 | ▲12.422 |
| Price To Earnings Ratio | -35.297 | ▼-19.121 | ▼-17.164 |
| Price To Earnings Growth Ratio | -0.980 | ▼-0.859 | ▼-0.401 |
| Forward Price To Earnings Growth Ratio | -0.980 | ▼-0.859 | ▼-0.401 |
| Price To Earnings Diluted Ratio | -35.297 | ▼-19.121 | ▼-17.164 |
| Price To Earnings Diluted Growth Ratio | -0.980 | ▼-0.859 | ▼-0.401 |
| Price To Book Ratio | 3.511 | ▼-1.063 | ▼-4.090 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -39.663 | ▼-0.351 | ▼-13.599 |
| Price To Operating Cash Flow Ratio | -39.663 | ▼-0.351 | ▼-13.599 |
| Debt To Assets Ratio | 0.001 | ▲0.001 | ▲0.001 |
| Debt To Equity Ratio | 0.001 | ▲0.001 | ▲0.001 |
| Debt To Capital Ratio | 0.001 | ▲0.001 | ▲0.001 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.021 | ▼-0.074 | ▼-0.144 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.461 | ▼-3.242 | ▼-1.043 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | -0.000 | -0.000 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -78.759 | ▼-78.759 | ▲108.938 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲1463480.200 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲1463480.200 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -30.784 | ▼-17.571 | ▼-14.908 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $483.9M | $251.8M | $24.7M | $150.7M | $200.2M | |
| Enterprise value | $422.3M | $205.9M | $17.4M | $142.5M | $179.9M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -34.61x | -32.16x | -2.21x | -19.72x | -24.58x | |
| EV / Free cash flow | -34.61x | -32.16x | -2.21x | -19.72x | -24.58x | |
| EV / EBITDA | -30.78x | -13.21x | -2.07x | -13.55x | -19.76x | |
| Net debt / EBITDA | 4.50x | 2.94x | 0.86x | 0.78x | 2.23x | |
| Current ratio | 51.35x | 11.47x | 4.17x | 4.21x | 12.98x | |
| Income quality | 0.89x | 0.41x | 0.94x | 0.69x | 0.80x | |
| Graham net-net | $19 | $5 | $0 | $1 | $2 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $137.7M | $55.0M | $5.6M | $10.0M | $18.9M | |
| Invested capital | $138.0M | $55.0M | $5.6M | $10.1M | $18.9M | |
| Return on assets | -9.7% | -25.9% | -114.4% | -79.5% | -44.4% | |
| Operating ROA | -16.6% | -47.8% | -85.9% | -62.4% | -48.8% | |
| Return on tangible assets | -9.7% | -25.9% | -114.4% | -79.5% | -44.4% | |
| Return on equity | -10.0% | -28.3% | -150.4% | -104.2% | -48.1% | |
| Return on invested capital | -12.1% | -29.4% | -158.0% | -104.3% | -48.2% | |
| Return on capital employed | -12.1% | -29.4% | -158.0% | -104.3% | -48.2% | |
| Earnings yield | -2.8% | -6.2% | -34.1% | -7.0% | -4.5% | |
| Free cash flow yield | -2.5% | -2.5% | -31.9% | -4.8% | -3.7% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | 0.0% | -0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+92.2%EV / Sales n/aEV / EBITDA ▼-133.0%EV / Op. cash flow ▼-2.450Earnings yield ▲+0.034
Profitability
Return on equity ▲+0.184Return on assets ▲+0.161Return on invested capital ▲+0.173Return on capital employed ▲+0.173Operating ROA ▲+0.312Income quality ▲+0.479Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+39.878Net debt / EBITDA ▲+1.557Working capital ▲+82690781.000Invested capital ▲+82945702.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+141.8%EV / Sales n/aEV / EBITDA ▼-55.8%EV / Op. cash flow ▼-10.026Earnings yield ▲+0.017
Profitability
Return on equity ▲+0.381Return on assets ▲+0.346Return on invested capital ▲+0.361Return on capital employed ▲+0.361Operating ROA ▲+0.322Income quality ▲+0.086Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+38.369Net debt / EBITDA ▲+2.266Working capital ▲+118786481.000Invested capital ▲+119041402.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-24 Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast Regenicin (OTCMKTS:RGIN - Get Free Report) and Monopar Therapeutics (NASDAQ: MNPR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Profitability This table compares Regenicin and Monopar Therapeutics'' net
- 2026-08-19 Monopar Appoints Jeffrey D. Kent, M.D. WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The Company also announced that two abstracts on ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate for the treatment of Wilson disease, have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.
- 2026-08-18 Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For ''Strong Buy'' Monopar Therapeutics (MNPR) remains a "Strong Buy," driven by exclusive license rights to ALXN1840 for Wilson disease and ongoing radiotherapeutic development. Completion of the rolling NDA for ALXN1840 in the coming months is a major catalyst, with potential FDA approval and Priority Review Voucher upside. ALXN1840 demonstrated statistically significant efficacy in phase 3, showing 3x copper mobilization over placebo and notable neurological improvement versus standard of care.
- 2026-08-13 Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.
- 2026-08-12 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced second quarter 2026 financial results and provided business updates.
- 2026-07-22 Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that it has initiated the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALXN1840 (tiomolibdate choline, TMC), its first-in-class albumin tripartite complex (“ATC”) activator for the treatment of Wilson disease. The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the remaining sections. Monopar has submitted the first completed sections of the NDA.
- 2026-07-20 Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the addition of seasoned commercial leaders to support the anticipated launch of the Company''s first commercial product, ALXN1840, pending U.S. Food and Drug Administration (FDA) approval.
- 2026-07-03 Monopar Therapeutics: ALXN1840''s Bull Case Has Improved Monopar Therapeutics has evolved from early radiopharma assets into a more concrete bet with ALXN1840 for rare diseases. ALXN1840 is their Wilson disease asset, which currently has a much clearer regulatory path, FDA designations, and even a possible Priority Review Voucher. MNPR''s financing also seems safer this time around as they prepare ALXN1840''s NDA and subsequent potential launch.
- 2026-06-30 Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company''s late-stage candidate for the treatment of Wilson disease.
- 2026-06-26 Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.